572 related articles for article (PubMed ID: 27678023)
1. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
2. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
[TBL] [Abstract][Full Text] [Related]
4. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
5. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
6. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
[TBL] [Abstract][Full Text] [Related]
7. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
[TBL] [Abstract][Full Text] [Related]
8. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
[TBL] [Abstract][Full Text] [Related]
9. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
[TBL] [Abstract][Full Text] [Related]
10. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
[TBL] [Abstract][Full Text] [Related]
11. LncRNA PVT1 facilitates DLBCL development via miR-34b-5p/Foxp1 pathway.
Tao S; Chen Y; Hu M; Xu L; Fu CB; Hao XB
Mol Cell Biochem; 2022 Mar; 477(3):951-963. PubMed ID: 35098439
[TBL] [Abstract][Full Text] [Related]
12. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
13. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.
Walker MP; Stopford CM; Cederlund M; Fang F; Jahn C; Rabinowitz AD; Goldfarb D; Graham DM; Yan F; Deal AM; Fedoriw Y; Richards KL; Davis IJ; Weidinger G; Damania B; Major MB
Sci Signal; 2015 Feb; 8(362):ra12. PubMed ID: 25650440
[TBL] [Abstract][Full Text] [Related]
14. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
16. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
Goatly A; Bacon CM; Nakamura S; Ye H; Kim I; Brown PJ; Ruskoné-Fourmestraux A; Cervera P; Streubel B; Banham AH; Du MQ
Mod Pathol; 2008 Jul; 21(7):902-11. PubMed ID: 18487996
[TBL] [Abstract][Full Text] [Related]
17. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
[No Abstract] [Full Text] [Related]
18. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations.
Wlodarska I; Veyt E; De Paepe P; Vandenberghe P; Nooijen P; Theate I; Michaux L; Sagaert X; Marynen P; Hagemeijer A; De Wolf-Peeters C
Leukemia; 2005 Aug; 19(8):1299-305. PubMed ID: 15944719
[TBL] [Abstract][Full Text] [Related]
19. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
Hu CR; Wang JH; Wang R; Sun Q; Chen LB
Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
[TBL] [Abstract][Full Text] [Related]
20. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]